Decipher Prostate Cancer Classifier regulatory update

GenomeDx said Medicare administrative contractor Palmetto GBA issued a draft local coverage determination (LCD) recommending coverage for GenomeDx's Decipher Prostate Cancer Classifier. The draft recommends the laboratory-developed test (LDT) to measure the risk of developing metastatic prostate cancer in men who have undergone radical prostatectomy. GenomeDx said Decipher is the only genomic test for prostate cancer to receive a draft LCD for use in the post-surgery setting. A 45-day comment period begins on Nov. 10. ...